BioCardia®, Inc. (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that additional data from the open label, roll-in cohort of the ongoing Phase III CardiAMP™ Heart Failure Trial (CardiAMP-HF Trial) are expected to be presented at three upcoming fall cardiovascular congresses.
|
SAN CARLOS, Calif., /PRNewswire/ -- BioCardia®, Inc. (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that additional data from the open label, roll-in cohort of the ongoing Phase III CardiAMP™ Heart Failure Trial (CardiAMP-HF Trial) are expected to be presented at three upcoming fall cardiovascular congresses. The CardiAMP-HF Trial is a study of the company's autologous, investigational CardiAMP stem cell therapy for the treatment of heart failure developed following a heart attack. Positive six-month outcomes from the first 10 patients were published online in Circulation Research in late August and are expected to be published in print in the September 28, 2018 issue. Two presentations related to CardiAMP are scheduled at the Transcatheter Cardiovascular Therapeutics (TCT) conference, one of the world's largest and most important educational meetings specializing in interventional cardiovascular medicine. Both presentations are scheduled for Monday, September 24, 2018:
An invited presentation - "The CardiAMP Heart Failure Trial" - is anticipated at the Texas Heart Institute International Cardiovascular Regenerative Medicine meeting, the leading U.S. conference focused on cardiovascular regenerative medicine, on October 5, 2018. An abstract has also been accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2018 conference. The presentation - "The CardiAMP Heart Failure Trial: Efficacy Outcomes from Roll-In Phase" - is scheduled for Monday, November 12, 2018 at 10:15 am CST. The CardiAMP-HF Trial is a 260-patient biotherapeutics study currently enrolling at up to 40 centers in the U.S. as an FDA-approved pivotal study. The Center for Medicare and Medicaid Services (CMS) has approved reimbursement for the trial, which also has grant support from the Maryland Stem Cell Research Fund. CardiAMP cell therapy uses a patient's own (autologous) bone marrow cells to potentially stimulate the body's natural healing response through a minimally-invasive, catheter-based procedure. About BioCardia Forward Looking Statements We may use terms such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately" or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2018, including those under the caption titled "Risk Factors." BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Investor Contact: Media Contact: SOURCE BioCardia, Inc. |
||
Company Codes: OTC-PINK:BCDA, OTC-QB:BCDA, OtherOTC:BCDA |
